Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor.
about
Identification of ARIA regulating endothelial apoptosis and angiogenesis by modulating proteasomal degradation of cIAP-1 and cIAP-2Microvascular complications and diabetic retinopathy: recent advances and future implicationsNovel pharmacotherapies in diabetic retinopathyAnimal models of age related macular degenerationDose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitusGene transfer by viral vectors into blood vessels in a rat model of retinopathy of prematurityMore weapons in the arsenal against ischemic retinopathyInhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin.Cell injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina.Nitric oxide is proangiogenic in the retina and choroid.Age-related macular degeneration: epidemiology and optimal treatment.Preventive versus treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization.Effective transfection of a cis element "decoy" of the nuclear factor-kappaB binding site into the experimental choroidal neovascularization.Pharmacologic therapy for diabetic retinopathy.Diabetic macular edema: classification, medical and laser therapy.Current and future pharmacological intervention for diabetic retinopathy.A review of drug options in age-related macular degeneration therapy and potential new agents.Emerging pharmacotherapies for diabetic macular edema.Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase.Animal models of choroidal and retinal neovascularization.Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels.The alternative complement pathway regulates pathological angiogenesis in the retinaDigoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization.Angiogenesis in epithelian ovarian cancer.Inhibition of reactive gliosis prevents neovascular growth in the mouse model of oxygen-induced retinopathy.A potential therapeutic strategy for inhibition of ocular neovascularization with a new endogenous protein: rhEDI-8t.Limited macular translocation.Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor.Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents.Gene therapy for retinal and choroidal diseases.HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin.A Quantitative and Standardized Method for the Evaluation of Choroidal Neovascularization Using MICRON III Fluorescein Angiograms in Rats.Fibrosis and diseases of the eye.Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization.Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachmentLymphocytic Microparticles Modulate Angiogenic Properties of Macrophages in Laser-induced Choroidal Neovascularization.Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy.Promising new treatments for neovascular age-related macular degeneration.Age-related macular degeneration: a practical approach to a challenging disease.Molecular targets for retinal vascular diseases.
P2860
Q24322043-D5DB7577-B356-4801-AAB8-D84816B337B9Q26822476-2231C99C-CA10-40D3-A596-28BFB5E563A1Q27002622-3A637EF9-5F0A-4A83-BD54-E2D4CF4478B1Q27004686-EAB4DAF6-CAAD-4324-92C2-AB9030D09F8DQ28281781-AA769B81-0364-49A4-A5B7-59CD1C36660BQ28344709-C9984877-572F-455D-8559-22F50D015435Q28362790-EEE12EA4-BC54-4E39-BD44-572FBF527DEBQ30686422-8EBC2439-9152-4234-BD95-07C95CA61E05Q30903366-96ED02F1-A148-49A2-AC54-E07E96F475E4Q31045998-4D889F64-21A9-4645-A7F3-A2B4D77FADB1Q31048292-2A594F4C-C10E-48C4-92D1-391D7C1BC6BAQ31101634-62838031-0E68-4161-8A49-13D22FA4391CQ33185693-38986AB0-DD53-47D4-996F-0B16DB64D7AFQ33194915-A04FE97E-2FA4-4043-845A-6BF99C178299Q33208471-A7CDCA39-FF67-4C01-9CA4-30D39BA1BC9EQ33216425-D5B95133-9347-4699-A586-C12EB56CC680Q33263803-D2C51AF3-A2F3-45CF-AF8B-DE6A359A8632Q33304852-1B6BDDE5-CAD9-46D1-9DC3-235ED2401060Q33351680-A4E01D99-163F-4694-99E0-772DBB316F9AQ33582933-48BFABB2-85D4-4B04-92F0-B65A6D45C0C4Q33584304-60F99C87-A9AB-457C-8F89-EB423938C29FQ33775122-2508826E-6ADF-415D-B545-BF703283A27EQ33868764-8E89C4B9-74BD-4C77-BFE5-4ACF6612F1C9Q33919078-63120788-F5BF-49FF-A174-E7E6CCA49990Q33968322-69356E85-0139-441D-AC11-FEF8C6B7BE69Q34007035-1A48E22C-7E0C-4698-8474-3594C4E16623Q34307055-6A017648-6EF4-47CB-ACEA-D9903F86643DQ34477473-B17D8E85-4A8D-4389-BF5F-DBCFD743F4BDQ34660821-12833EB8-0EA0-42FD-9A5E-89AE8E6F0B5AQ34701404-ADA888EE-984C-4900-B84A-1746E271F5BAQ34775400-5F750A0E-2EF9-4E5F-9499-AFC95169BB7EQ35646181-9CE9BF5C-EC2D-4E23-B50B-E21681F36DE9Q35649477-60C2535F-6B09-4A40-9025-CC781862455FQ35745444-A4C19B27-D2E8-4515-8EC8-014DF17EE388Q35747297-E0AFB582-7BF3-4B93-A780-1671814AF4B4Q36200878-AE28A8F7-2DC9-4995-8E5B-A9D00F50B0E8Q36397313-F9736A91-FC52-4DDA-8827-ADE5E90BB089Q36512564-4AE865FB-66A4-49E5-A18A-B614689BFC06Q36546345-0C14A874-196E-4261-B5EF-62B293FFBD38Q36667825-AB97D68D-9E7C-4D19-BE39-ED4A69353D1E
P2860
Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Dramatic inhibition of retinal ...... tration of a kinase inhibitor.
@ast
Dramatic inhibition of retinal ...... tration of a kinase inhibitor.
@en
type
label
Dramatic inhibition of retinal ...... tration of a kinase inhibitor.
@ast
Dramatic inhibition of retinal ...... tration of a kinase inhibitor.
@en
prefLabel
Dramatic inhibition of retinal ...... tration of a kinase inhibitor.
@ast
Dramatic inhibition of retinal ...... tration of a kinase inhibitor.
@en
P2093
P2860
P1476
Dramatic inhibition of retinal ...... tration of a kinase inhibitor.
@en
P2093
P A Campochiaro
P2860
P304
P356
10.1016/S0002-9440(10)65430-2
P407
P577
1999-06-01T00:00:00Z